Michael Gerlach, MD
Family Medicine · Mitchell, SDNPI 1962476093
Payments from drug & device makers
Across 740 payments — averaging $12.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Amgen$1K
- Pfizer$969
- Boehringer Ingelheim$953
- AstraZeneca$665
- Johnson & Johnson$613
- plus $3K from 35 others
What the payments were for
- Food & beverage$9,02098%
- Education$1712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 100 | $1,349 |
| Amgen | 119 | $1,343 |
| Pfizer | 94 | $969 |
| Boehringer Ingelheim | 82 | $953 |
| AstraZeneca | 19 | $665 |
| Johnson & Johnson | 103 | $613 |
| Merck | 37 | $407 |
| Novo Nordisk | 26 | $401 |
| Grifols USA, LLC | 16 | $270 |
| Astellas Pharma US Inc | 19 | $257 |
| AbbVie(2 entities) | 14 | $218 |
| Amarin Pharma, Inc. | 13 | $169 |
| Abbott | 10 | $165 |
| Sunovion Pharmaceuticals Inc. | 9 | $162 |
| Phathom Pharmaceuticals, Inc. | 8 | $149 |
| Novartis | 8 | $145 |
| E.r. Squibb & Sons, L.L.C. | 9 | $132 |
| Daiichi Sankyo Inc. | 7 | $125 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| GSK | 5 | $66 |
| Mylan Specialty L.p. | 4 | $63 |
| Sanofi-aventis U.S. LLC | 5 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $40 |
| Eisai Inc. | 2 | $32 |
| Medtronic | 2 | $30 |
| Lundbeck LLC | 2 | $28 |
| Exact Sciences | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 2 | $24 |
| Biogen | 2 | $23 |
| Conetic Solutions, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Mimedx Group, Inc. | 1 | $20 |
| Bayer | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$363
- SYMBICORT$243
- BEVESPI AEROSPHERE$243
- BREZTRI AEROSPHERE$128
- BREZTRI$119
How this compares
$9,190 in reported general payments places this provider in the 95th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 121 | $89,725 |
| EliquisApixaban | 89 | $84,870 |
| XareltoRivaroxaban | 69 | $64,121 |
| OzempicSemaglutide | 58 | $63,113 |
| FarxigaDapagliflozin Propanediol | 52 | $42,076 |
| JanuviaSitagliptin Phosphate | 53 | $41,807 |
| Repatha SureclickEvolocumab | 32 | $24,924 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $24,531 |
| MounjaroTirzepatide | 19 | $23,654 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $13,714 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,877 |
| Tetrabenazine | 14 | $11,084 |
| MyrbetriqMirabegron | 14 | $10,216 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $8,321 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $7,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $953 | $97,040134 claims |
| PfizerEliquis | $969 | $84,87089 claims |
| Johnson & JohnsonXarelto | $613 | $64,12169 claims |
| Novo NordiskOzempic | $401 | $63,11358 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $665 | $58,90889 claims |
| MerckJanuvia | $407 | $41,80753 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta, Shingrix | $66 | $30,08554 claims |
| Lilly USA, LLCMounjaro | $1,349 | $23,65419 claims |
| Astellas Pharma US IncMyrbetriq | $257 | $10,21614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Mitchell
- Paul RasmussenMitchell$3K
- Elizabeth JensenSioux Falls$106K
- Chad ThurySioux Falls$47K
- Kyla Helm-SwansonRapid City$22K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Jeffry MeyerSioux Falls$8K
- Scott BoyensSioux Falls$6K
- Terry GraberCuster$6K
- Christi ChildersSpearfish$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.